X
[{"orgOrder":0,"company":"Trianni","sponsor":"AbCellera","pharmaFlowCategory":"D","amount":"$90.0 million","upfrontCash":"$90.0 million","newsHeadline":"AbCellera Expands Technology Stack with Acquisition of Trianni for $90 Million","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"November 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Trianni"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$4,080.0 million","upfrontCash":"$80.0 million","newsHeadline":"Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Discovery Platform","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Silence Therapeutics"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
Details:
Under the agreement, Silence and AstraZeneca is focused on using Silence’s proprietary mRNAi GOLD™ platform to develop siRNA therapeutics for cardiovascular, renal, metabolic and respiratory diseases.
Lead Product(s):
siRNA Therapeutic
Therapeutic Area: Cardiology/Vascular Diseases
Product Name: Undisclosed
Highest Development Status: Discovery Platform
Product Type: Large molecule
Partner/Sponsor/Collaborator:
AstraZeneca
Deal Size: $4,080.0 million
Upfront Cash: $80.0 million
Deal Type: Collaboration
May 04, 2023
Details:
The acquisition deepens AbCellera’s technology stack with a suite of genetically engineered mice for generating diverse panels of human antibodies with drug-like properties.
Lead Product(s):
Human antibodies
Therapeutic Area: Cardiology/Vascular Diseases
Product Name: Undisclosed
Highest Development Status: Discovery Platform
Product Type: Large molecule
Partner/Sponsor/Collaborator:
AbCellera
Deal Size: $90.0 million
Upfront Cash: $90.0 million
Deal Type: Acquisition
November 18, 2020